Description

The PANX1 Knockout MDA-MB-231 Cell Line is a CRISPR/Cas9-edited knockout cell line that disrupts the PANX1 gene, generating a stable loss-of-function model for investigating pannexin-1-dependent processes. This cell line is derived from the widely used MDA-MB-231 human breast adenocarcinoma line and offers a genetically defined background to dissect PANX1-mediated ATP release, purinergic signaling, and intercellular communication. The knockout disrupts the functional expression of PANX1 large-pore channels without introducing additional genetic modifications, enabling precise studies of gene function in a metastatic cancer context.

The MDA-MB-231 parental cell line was originally isolated from the pleural effusion of a 51-year-old Caucasian female with metastatic mammary adenocarcinoma. It represents a highly aggressive triple-negative breast cancer (TNBC) model, lacking expression of estrogen receptor, progesterone receptor, and HER2, and is frequently employed to study tumor cell migration, invasion, and metastasis. These cells harbor additional mutations (e.g., in TP53 and KRAS) that contribute to their invasive phenotype, making them a standard system for anti-metastatic drug screening and molecular oncology research.

PANX1 encodes a large-pore plasma membrane channel that mediates the controlled release of ATP and other metabolites, acting as a conduit for paracrine and autocrine signals. PANX1 is activated by upstream regulators including the P2X7 receptor, caspases, intracellular calcium, TGF-??, mechanical stretch, and hypoxia. Its opening leads to ATP efflux, which in turn activates P2Y purinergic receptors, elevates cytosolic calcium, and promotes NLRP3 inflammasome assembly followed by caspase-1 cleavage and IL-1?? secretion. PANX1 also interacts with the actin cytoskeleton, Src family kinases, caspase-7, and connexins, linking it to cell migration and apoptotic volume regulation. Downstream, PANX1-mediated signaling can engage the MAPK/ERK pathway, contributing to proliferative and survival responses.

In the context of MDA-MB-231 cells, PANX1 channels are critical for the release of ATP that serves as a danger signal within the tumor microenvironment, fostering inflammation and facilitating metastatic dissemination. Knockout of PANX1 in this cell line abrogates ATP efflux, thereby disrupting paracrine communication with stromal and immune cells, attenuating NLRP3 inflammasome activation, and reducing invasive capacity. This model thus provides a powerful tool to dissect the contribution of pannexin-1 to key hallmarks of triple-negative breast cancer, including immune evasion, matrix degradation, and chemoresistance.

The PANX1 Knockout MDA-MB-231 Cell Line is ideally suited for a wide range of experimental applications, including the study of ATP-mediated intercellular communication, inflammasome regulation in TNBC, and the molecular mechanisms underlying metastasis. Researchers can employ this line in ATP release assays, transwell migration and invasion assays, co-immunoprecipitation with P2X7, western blotting and RT-qPCR for PANX1 validation, and phospho-ERK analysis. It is also valuable for anti-metastatic drug screening and for evaluating PANX1 as a therapeutic target, particularly in studies using cisplatin or paclitaxel. For additional information or technical support, please contact Ascent Research.